Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 198

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 198
---
apital recognized from the associated warrant exercises. The amount of the non -cashequity issuance cost recognized for the warrant modification used the Black -Scholesoption pricing model to determine the incremental fair value of the modified Class D Common Stock Existing Warrants immediately before and after the warrant modification (see Note 10). Additionally, using the Black -Scholesoption pricing model, the Class E Common Stock Warrants issued in connection with the Class D Warrant Inducement are treated as equity and the Company recognized approximately $4.9 million as a non -cashequity issuance cost netted against the additional paid -incapital (see Note 10). Total cash and non -cashequity issuance costs recognized in the Class D Common Stock Existing Warrants modification and the issuance of the Class E Common Stock Warrants of $5.5 million include cash equity issuance costs of $0.3 million and non -cashequity issuance costs of approximately $5.2 million. As of December 31, 2024, there are 80,940 Class D Common Stock Warrants outstanding to purchase 5,060shares of common stock that were not included in the Class D Warrant Inducement. Class E Warrant Inducement On December 3, 2024, the Company entered into warrant exercise inducement offer letters (the “December 2024 Inducement Letters”) with the holders of the Class E Common Stock Warrants (the “Class E Holders”) for 4,064,040 existing Class E Common Stock Warrants exercisable for an aggregate of 254,002shares of common stock (the “Class E Common Stock Existing Warrants”), to exercise their warrants at an exercise price of $16.00 per share, in exchange for the Company’s agreement to issue 4,064,040 Class F Common Stock Warrants for 254,002shares of its common stock (the “Class F Common Stock Warrants”) and 6,096,060 Class G Common Stock Warrants for 381,004shares of its common stock (the “Class G Common Stock Warrants”). The aggregate net proceeds from the exercise of the Class E Common Stock Existing Warrants, was $3.7 million. F-15 REVELATION BIOSCIENCES, INC. Notes to the Consolidated Financial Statements 6. 2024 Public Offering (cont.) In consideration for the immediate exercise of the Class E Common Stock Existing Warrants for cash, the exercising